# EDGAR Filing Document

**Accession Number:** 0002022416
**File Stem:** 0001178913-25-003278
**Filing Date:** 2025-9
**Character Count:** 2539
**Document Hash:** 7b7d950e44e7ce5c98989622c05527f7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-25-003278.hdr.sgml**: 20251205

**ACCESSION NUMBER**: 0001178913-25-003278

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250909

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Silexion Therapeutics Corp
- **CENTRAL INDEX KEY:** 0002022416
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 12 ABBA HILLEL ROAD
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5250606
- **BUSINESS PHONE:** 972-8-6286005

**MAIL ADDRESS:**
- **STREET 1:** 12 ABBA HILLEL ROAD
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5250606

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Biomotion Sciences
- **DATE OF NAME CHANGE:** 20240506

------

Silexion Therapeutics Corp.

12 Abba Hillel Road

Ramat Gan, Israel 5250606

September 9, 2025

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| **Re:** | **Silexion Therapeutics Corp.** |
|  | **Registration Statement on Form S-1**<br> **Filed September 5, 2025**<br> **File No. 333-290074** |

---

<u>VIA EDGAR</u>

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Silexion Therapeutics Corp. (the "**Company**") hereby respectfully requests that the effectiveness of the Registration Statement on Form S-1 (File No. 333-290074) of the Company (the "**Registration Statement**") be accelerated so that the Company's Registration Statement will become effective at 9:00 a.m., Eastern Time, on September 11, 2025 or as soon thereafter as may be practicable.

The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, Greenberg Traurig, LLP, by calling Gary Emmanuel at (212) 801-9337. The Company hereby authorizes Mr. Emmanuel to orally modify or withdraw this request for acceleration.

---

| |
|:---|
| &nbsp;&nbsp;&nbsp; Very truly yours, |
| &nbsp;&nbsp;&nbsp; SILEXION THERAPEUTICS CORP |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; By: | *<u>/s/ Ilan Hadar</u>* |
| &nbsp;&nbsp;&nbsp; Name: | Ilan Hadar |
| &nbsp;&nbsp;&nbsp; Title: | Chief Executive Officer |

---

cc: Gary Emmanuel (Greenberg Traurig, LLP)

------